Canada: Canadian Patent Law: 2015 Year In Review

This article summarizes noteworthy Canadian patent law decisions and developments from 2015.

1. Remedies in patent litigation

a. Non-infringing alternative defence introduced into Canadian patent law

A successful patentee in a patent infringement action is entitled to monetary compensation in relation to the acts of infringement.  In this regard, the patentee may elect to recover either its damages or the profits made by the infringer as a result of the infringement. 

With respect to damages, the Court will determine the financial harm suffered by the patentee as a result of the infringement.  In other words, the Court will consider what position the patentee would have been in but for the infringer's infringement.  Traditionally, compensatory damages for a patentee mainly comprise the patentee's lost profits on infringing sales it can prove (on a balance of probabilities) it would have made had the infringing product not been on the market, and a reasonable royalty for all other infringing sales. Until recently, the issue of damages was determined without factoring in what the infringer could or would have done differently. That is, the Court's damages analysis focused solely on the harm suffered by the patentee due to the infringer's acts of infringement. This is in contrast to an accounting of profits analysis, which may take into account any non-infringing alternatives available to an infringer.1

The law of damages changed in 2015 when the Federal Court of Appeal issued its decision in Apotex Inc. v. Merck & Co., Inc., 2015 FCA 171 (the "FCA Decision"). Prior to the FCA Decision, hypothetical non-infringing alternative (NIA) scenarios of a defendant were not considered when calculating patent infringement damages. However, the FCA Decision provided that, in certain situations, an infringer may now argue that it had an NIA available to it such that, for example, the infringer would have in any event made the sales, thereby defeating a patentee's claim for lost profits.

In order for an infringer to successfully rely upon the NIA defence, various minimum criteria must be met, including that, at the time of infringement, the infringer had an adequate supply of product such that it could have sold the non-infringing alternative, and the infringer would have actually sold the non-infringing alternative product.

Although the FCA Decision changes the law of Canada by introducing the NIA defence, Apotex was ultimately not successful in its appeal of the lower Court decision, which granted Merck damages totaling a staggering $119 million plus interest (as discussed in greater detail here). Instead, the Court of Appeal held that Apotex neither could nor would have sold a non-infringing alternative product. 

Leave to appeal to the Supreme Court of Canada has been sought by Apotex.  An in-depth review of the FCA Decision and its implications is available here.

b. Cases addressing damages under section 8 of the PM(NOC) Regulations

2015 saw further setbacks for generics under section 8 of the PM(NOC) Regulations in their attempts to recover innovator profits rather than their own loss suffered. One case addressing this issue was Apotex v. Eli Lilly, 2015 ONCA 305, where the Ontario Court of Appeal (OCA) held that a generic cannot make a claim for innovator profits under the doctrine of unjust enrichment. The case is discussed further here.

Apotex argued that it was kept off the market because of a proceeding under the PM(NOC) Regulations commenced by Lilly in which Lilly was ultimately unsuccessful. Section 8 of the PM(NOC) Regulations states that a generic can recover any "loss suffered" from an innovator in this situation. Apotex pursued a claim in the Ontario Courts under the doctrine of unjust enrichment. The three part test to make out a claim for unjust enrichment requires: (a) an enrichment of the defendant; (b) a corresponding deprivation of the plaintiff; and (c) the absence of any juristic reason for the enrichment.

The OCA held that Apotex could not recover Lilly's profits as Apotex suffered no corresponding deprivation. As Apotex had every right to claim its loss, any difference between this "loss suffered" and Lilly's actual profits was not a deprivation to Apotex.

Apotex made the further argument that this potential difference between Lilly's profits and Apotex's loss should nonetheless be recoverable as they were "profits of wrongdoing". Rejecting this argument, the OCA held that Apotex was an inappropriate party to make this claim, as Lilly had no equitable duty to Apotex and was not exploiting Apotex to its advantage.

Apotex has sought leave to the Supreme Court of Canada.

Low v. Pfizer, 2015 BCCA 506,was a decision of the BC Court of Appeal (BCCA). The case involved a potential class action on the basis that Pfizer overcharged the public for its VIAGRA product through asserting its ultimately invalid patent covering the use of sildenafil for the treatment of ED in proceedings under the PM(NOC) Regulations.

The most interesting aspect of Low is the BCCA's use of the "complete code" argument to dismiss the class action. In particular, it was held that the Patent Act and the related legislation (such as the PM(NOC) Regulations) constitute a complete code that "forecloses parallel civil actions". An in-depth discussion of Low can be found here.

Finally, the Supreme Court of Canada dismissed the appeal of Sanofi in the Ramipril section 8 damages case.2 The SCC endorsed the reasons of the Federal Court of Appeal. The FCA's reasons are discussed here.

2. Canada and the Trans-Pacific Partnership

The Trans-Pacific Partnership (TPP) is a trade agreement involving a dozen Pacific region countries that, collectively, make up 36% of global GDP (or close to $30 trillion in GDP). The TPP agreement addresses trade matters in relation to numerous industries, as well as certain intellectual property laws of TPP countries.

Specifically with respect to patents, the TPP agreement is notable in that it requires Canada to implement patent term extension in situations where there have been unreasonable delays (i.e., delays of more than five years from filing or three years from a request for examination). Making patent term extension available to patentees in Canada would bring Canada more in-line with countries such as the United States, which already has a regime for term extension. The TPP agreement also provides for patent term extension for pharmaceutical patent holders in situations where a patent was impacted by delays related to regulatory or marketing approvals, as well as other pharmaceutical-specific provisions addressing such matters as data protection and biologics. Much of the patent-related provisions of the TPP agreement are already consistent with Canadian law and/or proposed changes to Canadian law (based on, e.g., the Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union).

The TPP agreement has not been signed nor ratified by Canada and will be the subject of consultation in Canada. If ratification occurs, it will not be for some time. An in-depth discussion regarding the TPP agreement as it relates to Canadian patent law is available here.

3. Law regarding patent validity

The Federal Court continued to see a significant number of cases with patent validity at issue. Rather than discuss every decision, the following briefly canvasses some of the interesting legal findings made, as well as the special case of Amgen.

The Courts continued to consider the tie between disclosure and utility. Justice Rennie's 2014 Esomeprazole decision that there cannot be a disclosure requirement in cases of a sound prediction (except possibly for claims to a new use for an old compound) was cited with approval in Idenix v. Gilead, 2015 FC 1156. Further, on appeal, Justice Rennie's decision was upheld; however, the FCA did not consider the disclosure requirement for sound prediction (2015 FCA 158, discussed here).

The interplay between disclosure and utility also arose in the context of demonstrated utility. Early in the year, an obiter statement in Laboratoires Servier v. Canada, 2015 FC 108, suggested that a patent must make reference to a study that demonstrates any promise made. Later in the year, Justice Gleason held in the Eli Lilly v. Apotex decision (2015 FC 1016) that there is no requirement to provide evidence of utility in a patent.

Regarding obviousness, the decision of Eli Lilly v. Mylan, 2015 FCA 286 ("Cialis FCA"), was released in December. In recent years, several decisions of the Federal Court considered whether something was obvious to try by asking whether the skilled person had good reason to pursue predictable solutions or solutions that provide a "fair expectation of success". In Cialis FCA, Justice Dawson held that the "fair expectation of success" standard is inappropriate for determining whether an invention was obvious to try. Rather, Dawson JA framed the appropriate test as being whether the claimed invention was "more or less self-evident".

The FCA called for clarification in two areas of the law in Cobalt v. Bayer (2015 FCA 116, discussed here). One issue was the standard of review for construction. In obiter, Stratas JA's majority opinion questions whether a correctness standard is appropriate in considering construction in cases where the expert evidence played a significant role in informing the trial judge's construction. In particular, Stratas JA discussed the artificiality required in "cleaving off" aspects of claim construction that flow from the trial judge's appreciation of expert evidence from the words of the claim per se. Similar comments were made by Stratas JA in ABB Technology AG v. Hyundai Heavy Industries Co, Ltd (2015 FCA 181, discussed here).  Ultimately, the Court applied the correctness standard and left the question of the proper standard to be dealt with by the Supreme Court of Canada.

Cobalt v. Bayer also called for a thorough review of the method of medical treatment doctrine under Canadian law given that the statutory basis for the exception, the Patent Act's old section 41(1), has been repealed.

Finally, the Amgen Canada v. Apotex, 2015 FC 1261 decision was the first Federal Court decision pertaining to a biologic under the PM(NOC) Regulations, as we discussed previously. The decision considered among other things the validity issues of anticipation and obviousness.

Apotex's anticipation allegation was rejected because the prior art publication in question did not contain the same amino acid sequence as was claimed; in particular, the amino acid sequence in the prior art document did not begin with the amino acid "MET" as was required by the asserted claim.

However, the same prior art was relied on by Apotex in its successful obviousness allegation. In coming to this conclusion, Hughes J. noted that the work conducted by the inventors was "skilled work" as opposed to "creative work", and that the prior art document provided a direct motivation to the skilled person to undertake the work that the Amgen inventors performed.

4. Pharmaceutical regulatory update

a. Data protection decisions

2015 was a relatively busy year in terms of data protection, with two decisions being issued by the Federal Court. In Photocure ASA v. Canada, 2015 FC 959, the Court upheld the Minister of Health's denial of data protection to Cysview, an optical imaging agent designed to enhance detection of bladder cancer. In doing so, the Court found that the standard of review is reasonableness. This case is the first data protection judicial review to apply such a standard; all prior cases have applied the standard of correctness. The Court distinguished the established line of authority on the basis that questions of statutory interpretation were raised in those cases, while this case dealt merely with a question of fact. The state of data protection in Canada, and the Court's application in Photocure, are discussed in detail here.

In the second data protection decision of 2015, Hospira Healthcare Corporation v. Canada (Health), 2015 FC 1205, the Federal Court applied the established standard of correctness. The Photocure decision was confidential at the time Hospira was released, and therefore these two decisions stand in contrast to one another. Given the established line of authority in favour of a correctness standard, Photocure may simply be an outlier.

Notwithstanding the higher standard of correctness, the Court in Hospira upheld the Minister's application of data protection to post-filing amendments to a drug submission. That is, the Court confirmed that if a post-filing amendment makes a direct or indirect reference to an innovative drug subject to data protection, then the data protection provisions apply and the drug under review cannot be approved until the data protection term expires. A thorough summary of this case can be found here.

b. Patent Register: rules on product specificity relaxed

Innovator pharmaceutical companies benefitted from a relaxing of the strict product specificity requirements for listing pharmaceutical patents on the Patent Register pursuant to the PM(NOC) Regulations. As a result of prior Federal Court decisions, a patent could only be listed on the Patent Register against a drug with multiple medicinal ingredients if the patent contained a claim specifying all of the medicinal ingredients. If one medicinal ingredient was missing, the patent was not listable. In 2015, the PM(NOC) Regulations were amended to specifically allow to be listed patents claiming only one out of multiple medicinal ingredients in the approved drug.3

The Federal Court of Appeal in Eli Lilly Canada Inc v. Canada (Minister of Health), 2015 FCA 166 also relaxed the product specificity requirement. Prior to this decision, all medicinal ingredients in the approved drug had to be specifically named in the claim; it was not sufficient if the scope of the claim, as construed, included all medicinal ingredients. The Court of Appeal in Eli Lilly changed this analysis, stating that the claims do not need to specifically name all medicinal ingredients; the claim, as construed, must simply match the medicinal ingredients in the approved product.

The drug at issue in this case was Trifexis (spinosad and milbemycin oxime). The claims at issue claimed oral formulations containing spinosad, where oral formulation was defined in the disclosure as potentially including many other known parasitic treatments such as "milbemycins". The Court of Appeal found that the claims, as construed, claim an oral formulation of spinosad and milbemycin oxime, and therefore the patent was listable. The Court of Appeal's reasons are discussed here.

c. Patented Medicines Prices Review Board has jurisdiction over generics

In Canada (Attorney General) v. Sandoz Canada Inc, 2015 FCA 249, the Federal Court of Appeal upheld the Board's decision to retain jurisdiction over non-patent owners who sell patented medicines pursuant to a license or authorization from the patent owner (discussed here). Therefore, generic pharmaceutical companies Sandoz and ratiopharm were within the Board's jurisdiction.

The Board also withstood a constitutional challenge to the extent that the Board retains jurisdiction over non-patent owners. The challenge from Sandoz and ratiopharm alleged that the Board's current regime is one of pure price regulation and therefore intrudes into the Provinces' constitutional jurisdiction over property and civil rights. The Court of Appeal dismissed the challenge, finding that there is an integral connection between the Board and patents. Specifically, the Board seeks to prevent the harm arising by reason of the existence of a patent pertaining to the medicine being sold. 

Leave to appeal to the Supreme Court of Canada has been sought by Sandoz and ratiopharm.

5. Competition Bureau setting its sights on patent matters

In recent years, the Competition Bureau has shown a greater interest in intellectual property matters.  Most recently, the Bureau released its Intellectual Property Enforcement Guidelines (IPEGs) in draft form for public consultation.  The draft IPEGs address, among other things, when and how the Bureau will investigate certain conduct involving intellectual property.  In this regard, the draft IPEGs provide guidance regarding:

  • Settlements under the PM(NOC) Regulations: where an innovator pharmaceutical company settles with a generic pharmaceutical company with respect to early (pre-patent expiry) market entry by the generic, the Bureau may investigate situations involving any payments for the purpose of delaying generic entry.  Factors such as the fair market value of the generic's goods, the innovator's potential section 8 damages exposure and the innovator's litigation costs may be considered by the Bureau to determine the reasonableness of any payments.  In limited situations, the Bureau may investigate for criminal conspiracy violations, particularly where there is evidence that the intent of the payment was to fix prices, allocate markets or restrict output;
  • Conduct involving patent assertion entities (PAEs): PAEs that indiscriminately send cease and desist letters, or that are indifferent as to whether the allegations are misleading, may face liability for false or misleading representations, and/or deceptive marketing practices; and
  • Conduct involving standard essential patents (SEPs): where an entity fails to disclose patents that are essential during a standard-setting process (i.e., "patent ambush"), or where fair, reasonable and non-discriminatory licensing commitments are not respected, liability under the abuse of dominance provisions of the Competition Act may result.

At present, the IPEGs have not been finalized. The public consultation period ended on Aug. 10, 2015.


1 Monsanto Canada Inc. v. Schmeiser, 2004 SCC 34 at para. 102.

2 2015 SCC 20.

3 See new section 4(2.1).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
29 Nov 2017, Seminar, London, UK

Join us at 4 More London for this breakfast seminar on Wednesday, 29 November 2017 to gain a greater understanding on this debate. Coffee and breakfast will be from 08:30 with the discussion commencing at 09:00. We will finish and have you on your way by 10:00.

7 Dec 2017, Seminar, London, UK

Would you like the opportunity to hear more about the potential disruptive effect that blockchain is going to have in the energy sector? If so, please join us on 7 December where Jo-Jo Hubbard, a leading light in this area, will explain all.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.